Fig. 2

PKN1 rs34309238 variant influences pancreatic cancer risk by altering the level of phosphorylated PKN1 and thus affecting the FAK/PI3K/AKT signalling pathway. a Protein modification sites of PKN1. Annotations were obtained from the PhosphoSitePlus database. b Result of the iTRAQ-based comparative proteomics screen. PANC-1 cells were seeded in six-well plates after transfection with PKN1[A], PKN1[C] or control vector. The raw intensity values of cells transfection with PKN1[A] or PKN1[C] were divided by the intensity values of cells transfection with control vector to obtain the relative intensity values. The y axis shows the relative intensity values of cells' transfection with PKN1[A] minus the relative intensity values of cells' transfection with PKN1[C]. The x axis shows the molecular weight of detected peptides. The proteomics screen experiment was repeated independently for two times with similar results. c Levels of phosphorylated FAK and AKT were affected by the PKN1 rs34309238 variant. Cells were seeded in six-well plates after transfection with PKN1[A], PKN1[C] or control vector (left) and PKN1-targeting siRNAs or control siRNA (right). d Levels of phosphorylated FAK and AKT were reduced by the PKN1 inhibitors. Cells were seeded in six-well plates after transfection with PKN1 inhibitors Lestaurtinib and Ro318220 or DMSO as control. For c, d, the western blot experiment was repeated independently for three times with similar results